secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002059
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome licenses Zentalis' ROR1 ADC ZPC-21 and ADC platform for $35M upfront, up to $275M milestones
--------------------------------------------------------------------------------

- Exclusive worldwide license for preclinical ROR1 ADC ZPC-21; IND submission targeted for 1Q 2025.
- Upfront consideration: $35M in cash and Immunome common stock (2,298,586 shares).
- Zentalis eligible for up to $275M in milestone payments plus mid-to-high single-digit royalties.
- Immunome gains Zentalis' proprietary ADC platform technology for additional programs.
- Zentalis agrees to standstill restrictions and share transfer limitations for one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/0001104659-24-002059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/tm242340d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer